Work

Outcomes with drug-coated balloons versus drug-eluting stents for patients with de novo large-vessel coronary artery disease: an updated meta-analysis

Year: 2026
Type: article
Abstract: Randomized controlled trials have established the role of drug-coated balloon (DCB) for in-stent restenosis and small-vessel coronary artery disease. However, the role of DCB for large-vessel disease (LVD) remains not well established. Electronic databases were searched for studies comparing the clinical outcomes with DCB versus drug-eluting stents (DES) for de novo LVD. The primary outcome was target lesion revascularization (TLR). The secondary endpoints included cardiac mortality, all-cause mortality, myocardial infarction, and major adverse cardiac events (MACE). The angiographic outcomes were late lumen loss (LLL) and acute lumen gain. Summary estimates were pooled using a random-effects model. The pooled analysis showed lower TLR with DCB than DES (2.3% vs. 4.0%; OR = 0.58, 95% CI 0.35–0.98). DCB was associated with lower LLL (MD = − 0.18, 95% CI − 0.30 to − 0.10), whereas DES was associated with greater acute lumen gain (MD = − 0.52, 95% CI − 0.69 to − 0.34). There was no significant difference in MACE, cardiac mortality, all-cause mortality, or myocardial infarction, with pooled ORs (95% CIs) of 0.96 (0.54–1.70), 0.68 (0.37–1.26), 1.05 (0.77–1.43), and 1.05 (0.57–1.92), respectively. Among patients with LVD, DCB might be a reasonable alternative to DES. Additional randomized trials with longer follow-up are needed to confirm these findings.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,190
OpenAlex ID: W7235889280
FWCI:
Cites:
Cited by:
Related to: 10